Navigation

Summary of Results

Health Topic:   Mental health and behavioural conditions
Guidance:   Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine (replaced by TA217)
Description:   The summary of the withdrawn technology appraisal on Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine (replaced by TA217). It links to the withdrawn guidance and key documents.

NICE implementation uptake reports

Implementation uptake report Assessment Published Date Coverage
NICE Implementation Uptake Report: donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Doubts about or mixed impact in practice 2009 National

External literature

External literature Assessment Coverage

NHS Information Centre for Health and Social Care (2009) Use of NICE appraised medicines in the NHS in England-Experimental Statistics

Description: The NICE costing report expected the equivalent of 46.6 thousand patients (allowing for those who discontinued treatment) would be treated each year leading to an estimate of 16,999 thousand daily doses annually, assuming each patient receives 365 doses per year. The observed use was 34,017 thousand defined daily doses, a ratio of 2.0 to 1.

Practice appears not to be in line with guidance National

The NHS Information Centre for Health and Social Care (2011) Use of NICE-appraised medicines in the NHS in England-2009, Experimental Statistics

Description: This is the second report commissioned by the Metrics Working Group to look at the variation in use of postively appraised medicines in relation to the expected use as predicted by NICE. In all, 47 medicines in 18 groups, relating to 29 technology appraisals were considered. Out of the 12 groups where a comparison could be made (these are presented in Section 1 of the technology section results), observed use by the NHS in England was higher than the predicted use for eight and lower for three.

Not graded National

Richards, M (2010) Extent and causes of international variation in drug usage: A report for the Secretary of State for Health by Professor Sir Mike Richards CBE

Description: This report looks at medicines usage between countries, using IMS Health data. The WHO defined daily dose or the maximum or prescribed daily dose was used to measure usage. Results rank the UK relative to other countries usage and present calculations showing how close or otherwise the UK is to the average use across groups of other countries. It should be noted that countries other than the UK would not be expected to adhere to NICE guidance making comparisons between countries not possible.

Not graded National

This page was last updated: 26 January 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.